Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q1 2025 · 10-Q
Revenue$1.46M$1.46M−39.3% vs Q1 2024 Net Income-$15.09M-$15.09MN/M vs Q1 2024 EPS Diluted-$0.12-$0.12N/M vs Q1 2024 Operating Income-$18,084,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,100,000N/M Margins · derivedOperating margin-1242.9%−453.4 pt vs Q1 2024
Net margin-1036.8%−330.3 pt vs Q1 2024
ended Mar 31, 2025 · filed May 8, 2025 · 38 d after period end